Impact of YMDD mutations during lamivudine therapy in patients with chronic hepatitis B

Antiviral Chemistry and Chemotherapy, Supplement

Volumn 12, Issue 1, 2001, Pages 67-71

  Liaw, Y F ^a  

^a CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

Author keywords

Covalently closed circular DNA (cccDNA); Cytotoxic T lymphocyte; HBV DNA; Hepatitis B e antigen seroconversion; Hepatitis flare

Indexed keywords

ALANINE AMINOTRANSFERASE; LAMIVUDINE; NUCLEOSIDE DERIVATIVE; TETRAPEPTIDE; TYROSYLMETHIONYLASPARTYLASPARTATE; UNCLASSIFIED DRUG; VIRUS DNA;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; CLINICAL FEATURE; CONFERENCE PAPER; COST EFFECTIVENESS ANALYSIS; DISEASE COURSE; DISEASE EXACERBATION; DNA DAMAGE; DRUG EFFICACY; GENE LOCUS; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; LIVER CELL DAMAGE; LONG TERM CARE; MUTATION RATE; NONHUMAN; PRIORITY JOURNAL; TREATMENT OUTCOME; VIRUS INHIBITION; VIRUS LOAD; VIRUS MUTANT; VIRUS MUTATION; VIRUS REPLICATION;

ANTIVIRAL AGENTS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; LAMIVUDINE; MUTATION; VIRUS REPLICATION;

DNA VIRUSES; HEPATITIS B VIRUS;

EID: 0034815011     PISSN: 13502816     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (43)

1. Anti-HIV and anti-HBV activity and resistance profile of 2′, 3′-dideoxy-3′-thiacytidine (3TC) and its arylphosphoramidate derivative CF 1109
2. Long-term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus-infected patients
3. A trans-activator function is generated by integration of hepatitis B virus preS/S sequences in human hepatocellular carcinoma DNA
4. Incremental increases in HBeAg seroconversion and continued ALT normalization in Asian chronic HBV (CHB) patients treated with lamivudine for four years
5. Pretherapy alanine transaminiase level as a deterant for hepatitis B e antigen seroconversion during lamivudine therapy in patients with chronic hepatitis B
6. Consensus statements on the prevention and management of hepatitis B and hepatitis C in the Asia-Pacific region
7. A preliminary trial of lamivudine for chronic hepatitis B infection
8. Lamivudine as initial treatment for chronic hepatitis B in the United State
9. Inhibition of the replication of hepatitis B virus in vitro by 2′, 3′-dideoxy-3′thiacytidine and related analogues
10. Role of additional mutations outside the YMDD motif of hepatitis B virus polymerase in L(-)SddC (3TC) resistance
11. Efficacy of long-term lamivudine monotherapy in patients with hepatitis B e antigen-negative chronic hepatitis B
12. Lamivudine resistance in immunocompetent chronic hepatitis B
13. Mutations in the hepatitis B virus polymerase gene associated with antiviral treatment for hepatitis B
14. The preS2/S region of integrated hepatitis B virus DNA encodes a transcriptional transactivator
15. A one-year trial of lamivudine for chronic hepatitis B
16. Long-term therapy of chronic hepatitis B with lamivudine
17. t transactivator is generated by 3′ truncations within a defined region of the S gene
18. Nucleoside analogues in the treatment of chronic hepatitis B
19. Determinants for hepatitis B e antigen clearance in chronic type B hepatitis
20. Acute exacerbation in hepatitis B e antigen positive chronic type B hepatitis: A clinicopathological study
21. Acute exacerbation in chronic type B hepatitis: Comparison between HBeAg and antibody-positive patients
22. Pathogenesis and clinical significance of acute exacerbations and remissions in patients with chronic hepatitis B virus infection
23. Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy
24. Dramatic responses to lamivudine therapy following corticosteroid priming in chronic hepatitis B
25. Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B
26. Prednisolone priming enhances Th1 response and efficacy of subsequent lamivudine therapy in patients with chronic hepatitis B
27. Selection of mutations in the hepatitis B virus polymerase during therapy of transplant recipients with lamivudine
28. Evolution of hepatitis B virus polymerase gene mutations in hepatitis B e antigen-negative patients receiving lamivuidne therapy
29. Hepatitis B therapy: The plot thickens
30. Lamivudine therapy of WHV-infected woodchucks
31. Hepatitis B virus mutants associated with 3TC and famciclovir administration are replication defective
32. Lamivudine therapy for chronic hepatitis B: A six-month randomized dose-ranging study
33. Identification of more than one mutation in the hepatitis B virus polymerase gene arising during prolonged lamivudine treatment
34. YMDD motif in hepatitis B virus DNA polymerase influences on replication and lamivudine resistance: A study by in vitro full-length viral DNA transfection
35. The impact of drug resistance on the effectiveness of chemotherapy for chronic hepatitis B
36. Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: A randomised trial
37. Hepatic decompensation associated with hepatitis B e antigen clearance in chronic type B hepatitis
38. Early detection of viral resistance by determination of hepatitis B virus polymerase mutations in patients treated by lamivudine for chronic hepatitis B
39. Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B
40. Mutation in HBV RNA-dependent DNA polymerase confers resistance to lamivudine in vivo
41. In hepatocytes infected with duck hepatitis B virus, the template for viral RNA synthesis is amplified by an intracellular pathway
42. Clearance of the original hepatitis B virus YMDD-motif mutants with emergence of distinct lamivudive-resistant mutants during prolonged lamivudine therapy
43. Drug therapy for chronic hepatitis B: Antiviral efficacy and influence of hepatitis B virus polymeras mutations on the outcome of therapy